Back to discover
Drug

Ceralasertib

In clinical development
ClassSerine-protein kinase ATR inhibitorEmerging researchLate-stage development
RxNorm2216166ChEMBLCHEMBL4285417UNII85RE35306Z
2
Research papers
20
Active clinical trials
ATR
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

ATARI: ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss

Clinical trial2026-08-01Primary completion · ClinicalTrials.gov

EFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women With Ovarian Cancer Who Have Progressed During PARP Inhibition

Clinical trial2026-07-16Results expected Q4 2026 · ClinicalTrials.gov

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

Clinical trial2026-07-10Results expected Q1 2031 · ClinicalTrials.gov

A Randomized Phase III Trial of Checkpoint Blockade in Lung Cancer Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)

Clinical trial2026-07-02Results expected Q2 2028 · ClinicalTrials.gov

A Phase II Study of Chemo-Immunotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Big Ten Cancer Research Consortium BTCRC-LUN18-363

Clinical trial2026-07-01Primary completion · ClinicalTrials.gov

A Phase II Study of Olaparib and AZD6738 in Isocitrate Dehydrogenase (IDH) Mutant Solid Tumors

Clinical trial2026-06-17Results posted · ClinicalTrials.gov

Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)

Clinical trial2026-06-17Results expected Q1 2027 · ClinicalTrials.gov

Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor Malignancies

Clinical trial2026-04-23Results expected Q1 2028 · ClinicalTrials.gov

PRISM: PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab With or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Clinical trial2026-03-30Results expected Q4 2028 · ClinicalTrials.gov

Overcoming PARP Inhibitor Resistance in BRCA Germline Mutation Positive Advanced Breast Cancer

Clinical trial2026-03-05Results expected Q4 2027 · ClinicalTrials.gov

The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.

Research2024-02-24Nature communications

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.

Research2024-02-13Nature medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Ceralasertib
RxNorm CUI
2216166
ChEMBL ID
CHEMBL4285417
UNII
85RE35306Z
Primary mechanism
Serine-protein kinase ATR inhibitor

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Serine/threonine-protein kinase ATR
ATR · Q13535
INHIBITORSerine-protein kinase ATR inhibitor

Clinical trials

27 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
27
registered trials across all phases
LATEST COMPLETION 2025
20
Active studies
6
Recruiting
2
Late-stage (III+)
3
Completed
4
Discontinued
PHASE DISTRIBUTIONn = 27
Phase 17Phase 1 / 21Phase 217Phase 32

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)

CompletedPH IIAstraZenecan=542025

A Phase 1, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Ceralasertib Administered to Japanese Patients With Advanced Solid Malignancies

CompletedPH IAstraZenecan=122024

A Clinical Trial to Investigate Biomarker Effects of Pre-Surgical Treatment With DDR Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) Who Are Planned to Undergo Surgery That is Likely to be Followed by Radiotherapy and/or Chemotherapy.

CompletedPH IAstraZenecan=212021

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes8
Indoles2Morpholines2Pyrimidines2Sulfonamides2Antineoplastic Agents1Carcinoma, Non-Small-Cell Lung1CD8-Positive T-Lymphocytes1Lung Neoplasms1
Journals, researchers & institutions
Top journals
  • Nature communications1
  • Nature medicine1
Leading researchers
  • Barrett JC2
  • Barry ST2
  • Dean E2
  • Iyer S2
  • Ambrose HJ1
  • Aronson B1
  • Awad MM1
  • Baker T1
Leading institutions
free-text, unnormalised
  • Asan Medical Center1
  • Bloomberg-Kimmel Institute for Cancer Immunotherapy1
  • Centre Hospitalier de l'Université de Montréal1
  • Centre Hospitalier Universitaire Nantes1
  • Cross Cancer Institute1
  • Dana-Farber Cancer Institute1

Related drugs

2 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Platinum

Studied across 3 of the same disease areas as Ceralasertib in the shared literature.

3 shared diseases1 shared paper
Durvalumab

Studied across 2 of the same disease areas as Ceralasertib in the shared literature.

2 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials